Schrodinger, Inc. SDGR
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
4/9
Piotroski F — financial health
-0.33
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $255.9M | -$103.3M | $142.6M | $12.5M | $364.1M |
| 2024 | $207.5M | -$187.1M | $132.1M | -$164.7M | $421.4M |
| 2023 | $216.7M | $40.7M | $140.7M | -$150.1M | $548.6M |
| 2022 | $181.0M | -$149.2M | $101.0M | -$127.7M | $447.9M |
| 2021 | $137.9M | -$100.4M | $65.6M | -$77.8M | $557.1M |
| 2020 | $108.1M | -$24.5M | $63.5M | $14.2M | $624.0M |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -0.33 (distress)
- Working capital / assets 0.455
- Retained earnings / assets -0.866
- EBIT / assets -0.23
- Equity / liabilities 1.005
Source: SEC EDGAR filings · CIK 0001490978 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.